RadNet's $269M AI Power Play
Outpatient imaging giant RadNet is acquiring French AI developer Gleamer for $269 million, a move to vertically integrate AI into its DeepHealth platform. The deal makes DeepHealth the world's largest clinical AI provider for radiology, aiming to tackle imaging volumes and radiologist shortages with automated tools. RadNet plans to begin deploying the new tech by Q3 2026 to reengineer its entire workflow.
RadNet's acquisition of Gleamer is part of a larger strategy of vertical integration, building on prior purchases of AI companies like Aidence (lung cancer), Quantib (prostate cancer), and DeepHealth (breast cancer) to create a comprehensive cancer screening platform. This latest deal adds a robust portfolio for routine imaging, particularly in high-volume X-rays, which make up nearly a quarter of RadNet's imaging procedures. Gleamer, founded in 2017, has shown significant growth, with a compound annual growth rate exceeding 90% from 2022 to 2025 and an expected $30 million in annual recurring revenue for 2026. The company's AI solutions, which include four FDA-cleared devices, have already been used to analyze over 30 million exams across 700 customer sites in 44 countries. This move occurs as the outpatient imaging market experiences significant tailwinds. Payers are increasingly directing patients toward lower-cost, freestanding centers, a trend expected to save the U.S. healthcare system up to $125 billion annually. Furthermore, CMS is phasing out its "inpatient-only" list, which will shift more procedures, including 285 mostly musculoskeletal services in 2026, to outpatient settings. Consolidation within the diagnostic imaging sector is rampant, fueled by private equity investment and the operational pressures on smaller practices. Between 2013 and 2023, private equity firms acquired 151 radiology practices, resulting in 12% of all U.S. radiologists being employed by PE-backed entities by 2023. This trend is a response to declining reimbursements and the capital required for advanced technology. For health systems, the rise of specialized outpatient imaging giants like RadNet presents a competitive threat, prompting many to develop their own freestanding imaging strategies through acquisitions, joint ventures, or building new facilities. The goal is to recapture patient leakage and manage care across different sites, from hospital outpatient departments to independent diagnostic testing facilities. RadNet's recent financial performance highlights its growth trajectory, with a reported 14.8% year-over-year revenue increase in Q4 2025, reaching $547.7 million. The company projects its Digital Health revenue, now bolstered by Gleamer, to grow by 46% to 56% in 2026.
